# Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor

> **NCT04023721** · PHASE2 · TERMINATED · sponsor: **F-star Therapeutics, Inc.** · enrollment: 64 (actual)

## Conditions studied

- Hepatitis B
- HBV
- Hepatitis B, Chronic

## Interventions

- **DRUG:** Inarigivir soproxil
- **DRUG:** Nucleoside/nucleotide (NUC) analogue inhibitors

## Key facts

- **NCT ID:** NCT04023721
- **Lead sponsor:** F-star Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-18
- **Primary completion:** 2020-07-16
- **Final completion:** 2020-07-16
- **Target enrollment:** 64 (ACTUAL)
- **Why stopped:** Safety
- **Last updated:** 2020-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04023721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04023721, "Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04023721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*